[HTML][HTML] The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind) …
RM Stone, S Mandrekar, BL Sanford, S Geyer… - Blood, 2015 - Elsevier
Background: Midostaurin (M) is a multi-targeted small molecule FLT3 inhibitor which has
single agent activity in both internal tandem duplication (ITD) and tyrosine kinase domain …
single agent activity in both internal tandem duplication (ITD) and tyrosine kinase domain …
[HTML][HTML] An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial …
RA Larson, SJ Mandrekar, BL Sanford, K Laumann… - Blood, 2017 - Elsevier
Background: Midostaurin (M) is an oral, multi-targeted, small molecule FLT3 inhibitor that
has single agent activity in both internal tandem duplication (ITD) and tyrosine kinase …
has single agent activity in both internal tandem duplication (ITD) and tyrosine kinase …
Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell …
R Schlenk, K Döhner, H Salih, A Kündgen, W Fiedler… - 2015 - ashpublications.org
Background: Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in
roughly 25% of younger adult patients (pts) with acute myeloid leukemia (AML), implicating …
roughly 25% of younger adult patients (pts) with acute myeloid leukemia (AML), implicating …
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
G Oñate, M Pratcorona, A Garrido, A Artigas-Baleri… - Blood cancer …, 2023 - nature.com
Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid
leukemia (AML) with FLT3 mutations (FLT3 mut). We analyzed the impact of midostaurin in …
leukemia (AML) with FLT3 mutations (FLT3 mut). We analyzed the impact of midostaurin in …
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar, BL Sanford… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
MT Voso, RA Larson, D Jones, G Marcucci… - Blood …, 2020 - ashpublications.org
The results from the RATIFY trial (ClinicalTrials. gov: NCT00651261; CALGB 10603)
showed that midostaurin combined with standard chemotherapy significantly improved …
showed that midostaurin combined with standard chemotherapy significantly improved …
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
RA Larson, SJ Mandrekar, LJ Huebner, BL Sanford… - Leukemia, 2021 - nature.com
The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance)
demonstrated a statistically significant overall survival benefit from the addition of …
demonstrated a statistically significant overall survival benefit from the addition of …
Midostaurin in acute myeloid leukemia: an evidence-based review and patient selection
Abstract Fms-related-tyrosine kinase 3 (FLT3) mutations occur in approximately a third of
acute myeloid leukemia (AML) patients and confer an adverse prognosis. Numerous studies …
acute myeloid leukemia (AML) patients and confer an adverse prognosis. Numerous studies …
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
RF Schlenk, D Weber, W Fiedler… - Blood, The Journal …, 2019 - ashpublications.org
Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD)
have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was …
have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was …
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
LK Schmalbrock, A Dolnik, S Cocciardi… - Blood, The Journal …, 2021 - ashpublications.org
In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …